The molecular mechanism underlying the therapeutic effects of EL20 is believed to involve stabilization of the mutant RyR2 channel from which calmodulin has been dissociated as a result of the CPVT variant.13 This evidence concerns the gene RYR2 and catecholaminergic polymorphic ventricular tachycardia.